Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
801-820 of 2,120 trials

High-Risk Neuroblastoma: Naxitamab and GM-CSF Treatment

We are studying a new treatment combining naxitamab and GM-CSF for children with high-risk neuroblastoma who have not responded to prior therapies. The trial aims to assess how well this treatment works and its safety.

Recurrent Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Multiple Myeloma: AZD0305 Treatment Study

We are investigating whether AZD0305, alone or with other cancer therapies, is safe and effective for adults with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Metastatic Breast Cancer: FDG-PET/CT vs. Conventional CT

We are studying whether FDG-PET/CT can better monitor treatment response in metastatic breast cancer patients compared to conventional CT. This may help improve survival and quality of life for those involved.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Preventing Blood Clots: REGN9933 and REGN7508 Study

We are studying two new medications to see if they can help prevent blood clots in adults with a peripherally inserted central catheter. The trial will also assess how safe these treatments are.

Venous Thromboembolism3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyHematology

Advanced Melanoma: Vusolimogene Oderparepvec with Nivolumab

We are comparing a new treatment combination for advanced melanoma that has worsened after other therapies. The goal is to see if this combination improves survival and response compared to standard treatment options.

Advanced MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Head and Neck Cancer: Dostarlimab Treatment Study

We are studying whether dostarlimab can improve outcomes for adults with locally advanced head and neck cancer after initial treatment. Participants will receive either the new treatment or a placebo to compare effects.

Squamous Cell Carcinoma of the Head and Neck3-6 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementOncology

Graft-Versus-Host Disease: Corticosteroids with ECP

We are studying whether adding extracorporeal photopheresis to corticosteroids helps patients with Grade II acute graft-versus-host disease after stem cell transplantation. This trial compares treatment outcomes and side effects between the two approaches.

Acute Graft-Versus-Host Disease (GVHD)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

BRAF V600E Mutated Metastatic Colorectal Cancer: ENCORAFENIB and FOLFIRI

We are studying a combination of ENCORAFENIB and FOLFIRI for patients with BRAF V600E mutated metastatic colorectal cancer that has progressed on previous treatments. The goal is to see if this combination can improve treatment outcomes and safety.

Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Crohn's Disease: Tulisokibart Treatment Study

We are testing a new medication, tulisokibart, for people with moderately to severely active Crohn's disease. The study aims to see if it helps reduce symptoms and achieve remission compared to a placebo.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Melanoma Treatment: LTX-315 and Pembrolizumab

We are studying a new treatment combination for patients with resectable stage III-IV melanoma. The goal is to see how well it shrinks tumors and affects overall health and quality of life.

Stage III Malignant Melanoma≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesDermatologyOncology

Systemic Lupus Erythematosus: SAR441344 Treatment Study

We are investigating a new medication for people with Systemic Lupus Erythematosus to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)16-20 visitsInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

C3 Glomerulopathy and ICGN: OMS906 Study

We are testing a new drug called OMS906 in patients with C3 Glomerulopathy or Idiopathic Immune Complex-Mediated Glomerulonephritis. The study aims to evaluate the safety and early effects of this treatment on kidney function.

Immune Complex Glomerulonephritis6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesNephrology

Thyroid Eye Disease: Lu AG22515 Treatment

We are investigating the effects of Lu AG22515 on eye bulging in adults with moderate-to-severe Thyroid Eye Disease. This study aims to see if it can improve symptoms related to this condition.

Thyroid Eye Disease1-2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Frontotemporal Dementia: DNL593 Study

We are evaluating the safety and tolerability of a new drug, DNL593, in healthy individuals and those with frontotemporal dementia. This study aims to understand how the drug works in the body and its effects over time.

Frontotemporal Dementia1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Gastrointestinal Cancers: MK-2870 Treatment Study

We are testing the safety and effectiveness of MK-2870, alone or with other cancer treatments, for people with gastrointestinal cancers. This study aims to see how well it works in reducing tumors and improving patient outcomes.

Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, and Biliary Tract Cancer6-12 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Acute Progressive Stroke: Norepinephrine Treatment

We are studying whether adding norepinephrine to standard care helps improve recovery in patients with acute progressive perforating artery stroke. The goal is to see if this combination leads to better functional outcomes and reduces complications.

Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Pancreatic Cancer: Neoadjuvant Triple Treatment Study

We are exploring a new combination of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer. The goal is to see if this treatment improves survival and surgical outcomes.

Pancreatic CancerBorderline Resectable Pancreatic Cancer (BRPC)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Progressive Supranuclear Palsy: 18F-PI-2620 PET Imaging Study

We are investigating a new imaging tool to help identify and understand progressive supranuclear palsy in patients. This study may improve diagnosis and treatment options for this rare neurological condition.

Parkinson's DiseaseProgressive Supranuclear Palsy>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNeurology

Vulvar Cancer: Chemoradiation Study

We are investigating if chemoradiation alone is a safe alternative to surgery for early-stage vulvar cancer patients with lymph node involvement. The study also evaluates the side effects of this treatment over time.

Vulvar Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Metastatic Colorectal and Gastroesophageal Cancer: Trifluridine/Tipiracil Study

We are studying the safety of Trifluridine/tipiracil as a new chemotherapy for patients with metastatic colorectal or gastroesophageal cancer who have a specific genetic deficiency. This trial aims to see if it can be a safer alternative to traditional treatments.

Metastatic Colon or Rectal Cancer with DPD Deficiency1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology